LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Boosting maternal and neonatal anti-SARS-CoV-2 humoral immunity using a third mRNA vaccine dose.

    Cahen-Peretz, Adva / Tsaitlin-Mor, Lilah / Allouche Kam, Hadas / Frenkel, Racheli / Kabessa, Maor / Cohen, Sarah M / Lipschuetz, Michal / Oiknine-Djian, Esther / Lianski, Sapir / Goldman-Wohl, Debra / Walfisch, Asnat / Kovo, Michal / Neeman, Michal / Wolf, Dana G / Yagel, Simcha / Beharier, Ofer

    JCI insight

    2023  Volume 8, Issue 1

    Abstract: Background: To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of ... ...

    Abstract Background: To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of available evidence regarding the impact of a third boosting dose during pregnancy, underscoring the urgent need for relevant data. We aimed to characterize the effect of the third boosting dose of mRNA Pfizer BNT162b2 vaccine in pregnancy.
    Methods: We performed a prospective cohort study of anti-SARS-CoV-2 antibody titers (n = 213) upon delivery in maternal and cord blood of naive fully vaccinated parturients who received a third dose (n = 86) as compared with 2-dose recipients (n = 127).
    Results: We found a robust surge in maternal and cord blood levels of anti-SARS-CoV-2 titers at the time of delivery, when comparing pregnancies in which the mother received a third boosting dose with 2-dose recipients. The effect of the third boosting dose remained significant when controlling for the trimester of last exposure, suggesting additive immunity extends beyond that obtained after the second dose. Milder side effects were reported following the third dose, as compared with the second vaccine dose, among the fully vaccinated group.
    Conclusion: The third boosting dose of mRNA Pfizer BNT162b2 vaccine augmented maternal and neonatal immunity with mild side effects. These data provide evidence to bolster clinical and public health guidance, reassure patients, and increase vaccine uptake among patients who are pregnant.
    Funding: Israel Science Foundation KillCorona grant 3777/19; Research grant from the "Ofek" Program of the Hadassah Medical Center.
    MeSH term(s) Infant, Newborn ; Female ; Pregnancy ; Humans ; SARS-CoV-2 ; COVID-19/prevention & control ; BNT162 Vaccine ; Immunity, Humoral ; Pandemics ; Prospective Studies ; Mothers ; RNA, Messenger ; mRNA Vaccines
    Chemical Substances BNT162 Vaccine ; RNA, Messenger
    Language English
    Publishing date 2023-01-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.158646
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Boosting Dose of Pfizer-BioNtech mRNA Vaccine Against SARS-CoV-2 Does Not Affect Reproductive Outcomes in In-Vitro Fertilization Patients: A Cohort Study.

    Adler Lazarovits, Chana / Smadja, Adama / Kabessa, Maor / Allouche Kam, Hadas / Nevo, Lea / Godin, Miri / Bentov, Yaakov / Beharier, Ofer / Esh Broder, Efrat / Holzer, Hananel / Hershko Klement, Anat

    Journal of women's health (2002)

    2022  Volume 32, Issue 1, Page(s) 24–28

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Male ; Female ; Pregnancy ; Humans ; Cohort Studies ; SARS-CoV-2 ; COVID-19 Vaccines ; COVID-19/prevention & control ; Semen ; Fertilization in Vitro ; Fertilization ; mRNA Vaccines
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2022-11-22
    Publishing country United States
    Document type Observational Study ; Journal Article
    ZDB-ID 1139774-3
    ISSN 1931-843X ; 1059-7115 ; 1540-9996
    ISSN (online) 1931-843X
    ISSN 1059-7115 ; 1540-9996
    DOI 10.1089/jwh.2022.0163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.

    Nevo, Lea / Cahen-Peretz, Adva / Vorontsov, Olesya / Frenkel, Rachelli / Kabessa, Maor / Cohen, Sarah M / Hamrani, Adar / Oiknine-Djian, Esther / Lipschuetz, Michal / Goldman-Wohl, Debra / Walfisch, Asnat / Kovo, Michal / Neeman, Michal / Yagel, Simcha / Wolf, Dana G / Beharier, Ofer

    American journal of obstetrics and gynecology

    2022  Volume 227, Issue 3, Page(s) 486.e1–486.e10

    Abstract: Background: Post-COVID-19 vaccine boosting is a potent tool in the ongoing pandemic. Relevant data regarding this approach during pregnancy are lacking, which affects vaccination policy guidance, public acceptance, and vaccine uptake during pregnancy. ... ...

    Abstract Background: Post-COVID-19 vaccine boosting is a potent tool in the ongoing pandemic. Relevant data regarding this approach during pregnancy are lacking, which affects vaccination policy guidance, public acceptance, and vaccine uptake during pregnancy. We aimed to investigate the dynamics of anti-SARS-CoV-2 antibody levels following SARS-CoV-2 infection during pregnancy and to characterize the effect of a single postinfection vaccine booster dose on the anti-SARS-CoV-2 antibody levels in parturients in comparison with the levels in naïve vaccinated and convalescent, nonboosted parturients.
    Study design: Serum samples prospectively collected from parturients and umbilical cords at delivery at our university-affiliated urban medical center in Jerusalem, Israel, from May to October 2021, were selected and analyzed in a case-control manner. Study groups comprised the following participants: a consecutive sample of parturients with a polymerase chain reaction-confirmed history of COVID-19 during any stage of pregnancy; and comparison groups selected according to time of exposure comprising (1) convalescent, nonboosted parturients with polymerase chain reaction-confirmed COVID-19; (2) convalescent parturients with polymerase chain reaction-confirmed COVID-19 who received a single booster dose of the BNT162b2 messenger RNA vaccine; and (3) infection-naïve, fully vaccinated parturients who received 2 doses of the BNT162b2 messenger RNA vaccine. Outcomes that were determined included maternal and umbilical cord blood anti-SARS-CoV-2 antibody levels detected at delivery, the reported side effects, and pregnancy outcomes.
    Results: A total of 228 parturients aged 18 to 45 years were included. Of those, samples from 64 were studied to characterize the titer dynamics following COVID-19 at all stages of pregnancy. The boosting effect was determined by comparing (1) convalescent (n=54), (2) boosted convalescent (n=60), and (3) naïve, fully vaccinated (n=114) parturients. Anti-SARS-CoV-2 antibody levels detected on delivery showed a gradual and significant decline over time from infection to delivery (r=0.4371; P=.0003). Of the gravidae infected during the first trimester, 34.6% (9/26) tested negative at delivery, compared with 9.1% (3/33) of those infected during the second trimester (P=.023). Significantly higher anti-SARS-CoV-2 antibody levels were observed among boosted convalescent than among nonboosted convalescent (17.6-fold; P<.001) and naïve vaccinated parturients (3.2-fold; P<.001). Similar patterns were observed in umbilical cord blood. Side effects in convalescent gravidae resembled those in previous reports of mild symptoms following COVID-19 vaccination during pregnancy.
    Conclusion: Postinfection maternal humoral immunity wanes during pregnancy, leading to low or undetectable protective titers for a marked proportion of patients. A single boosting dose of the BNT162b2 messenger RNA vaccine induced a robust increase in protective titers for both the mother and newborn with moderate reported side effects.
    MeSH term(s) Antibodies, Viral ; BNT162 Vaccine ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Humans ; Immunity, Humoral ; Infant, Newborn ; RNA, Messenger ; SARS-CoV-2 ; Vaccines, Synthetic ; Viral Vaccines/adverse effects ; mRNA Vaccines
    Chemical Substances Antibodies, Viral ; COVID-19 Vaccines ; RNA, Messenger ; Vaccines, Synthetic ; Viral Vaccines ; mRNA Vaccines ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-04-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80016-8
    ISSN 1097-6868 ; 0002-9378
    ISSN (online) 1097-6868
    ISSN 0002-9378
    DOI 10.1016/j.ajog.2022.04.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pregnancy outcomes among patients with recurrent pregnancy loss and chromosomal aberration (CA) without PGD.

    Kabessa, Maor / Harlev, Avi / Friger, Michael / Sergienko, Ruslan / Litwak, Baila / Koifman, Arie / Steiner, Naama / Bashiri, Asher

    Journal of perinatal medicine

    2017  Volume 46, Issue 7, Page(s) 764–770

    MeSH term(s) Abortion, Habitual/epidemiology ; Abortion, Habitual/etiology ; Abortion, Habitual/genetics ; Adult ; Chromosome Aberrations ; Cohort Studies ; Female ; Humans ; Infant, Newborn ; Israel/epidemiology ; Karyotype ; Live Birth/epidemiology ; Male ; Pregnancy ; Pregnancy Outcome ; Preimplantation Diagnosis ; Prognosis ; Retrospective Studies
    Language English
    Publishing date 2017-06-29
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 123512-6
    ISSN 1619-3997 ; 0300-5577 ; 0936-174X
    ISSN (online) 1619-3997
    ISSN 0300-5577 ; 0936-174X
    DOI 10.1515/jpm-2016-0408
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Ovarian follicular function is not altered by SARS-Cov-2 infection or BNT162b2 mRNA Covid-19 vaccination.

    Bentov, Yaakov / Beharier, Ofer / Moav-Zafrir, Arbel / Kabessa, Maor / Godin, Miri / Greenfield, Caryn / Ketzinel-Gilad, Mali / Esh Broder, Efrat / Holzer, Hananel / Wolf, Dana / Oiknine-Djian, Esther / Barghouti, Iyad / Goldman-Wohl, Debra / Yagel, Simcha / Walfisch, Asnat / Hershko Klement, Anat

    medRxiv

    Abstract: Importance: This is the first study to examine the impact of SARS-Cov-2 infection and COVID-19 vaccination on ovarian function. Objective: To characterize anti-COVID-19 antibodies in follicular fluid and compare ovarian follicle function in women ... ...

    Abstract Importance: This is the first study to examine the impact of SARS-Cov-2 infection and COVID-19 vaccination on ovarian function. Objective: To characterize anti-COVID-19 antibodies in follicular fluid and compare ovarian follicle function in women following confirmed SARS-CoV-2 infection, COVID-19 vaccination, and non-infected, unvaccinated controls. Design: This is a cohort study conducted between February 1 and March 10, 2021. Setting: A single university hospital-based IVF clinic. Participants: Consecutive sample of female patients undergoing oocyte retrieval. Interventions: Consenting patients were recruited and assigned to one of three study groups: recovering from confirmed COVID 19 (n=9); vaccinated (n=9); and uninfected, non-vaccinated controls (n=14). Serum and follicular fluid samples were taken and analyzed for anti-COVID IgG as well as estrogen, progesterone and HSPG2 concentration, as well as the number and maturity of aspirated oocytes and previous estrogen and progesterone measurements. Main outcome measures: Follicular function, including steroidogenesis, follicular response to the LH/hCG trigger, and oocyte quality biomarkers. Results: Both natural and vaccine elicited anti-COVID IgG antibodies were detected in the follicular fluid in levels proportional to the IgG serum concentration. No differences were detected in any of the surrogate ovarian follicle quality reporting parameters. Conclusions and relevance: Both SARS-COV-2 infection and vaccination with the BNT162b2 mRNA vaccine mediate IgG immunity that crosses into the follicular fluid. No detrimental effect on follicular function was detected.
    Keywords covid19
    Language English
    Publishing date 2021-04-13
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.04.09.21255195
    Database COVID19

    Kategorien

To top